Publications

Cancers

Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group.

29-09-2021

Nature communications

Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer.

27-09-2021

Annals of oncology : official journal of the European Society for Medical Oncology

Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al.

01-09-2021

Annals of oncology : official journal of the European Society for Medical Oncology

'IMpassionate conflicts' in immunotherapy trials for metastatic triple-negative breast cancer.

01-08-2021

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Simultaneous analysis of E1 and E2 by LC-MS/MS in healthy volunteers: estimation of reference intervals and comparison with a conventional E2 immunoassay.

15-07-2021

Annals of oncology : official journal of the European Society for Medical Oncology

High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.

01-05-2021

European journal of cancer (Oxford, England : 1990)

Adjuvant chemotherapy in small node-negative triple-negative breast cancer.

01-08-2020

Molecular cancer research : MCR

The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor-Positive Breast Cancers.

01-07-2020

NPJ breast cancer

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.

22-05-2020

NPJ breast cancer

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.

16-05-2020

NPJ breast cancer

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group.

16-05-2020

Annals of oncology : official journal of the European Society for Medical Oncology

Mise en place: toward neoadjuvant chemoimmunotherapy for early triple-negative breast cancer.

01-05-2020

Nature medicine

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.

01-04-2020

The Journal of pathology

The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.

01-04-2020

Annals of oncology : official journal of the European Society for Medical Oncology

Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.

01-04-2020

European journal of cancer (Oxford, England : 1990)

Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.

01-03-2020

Breast cancer research : BCR

Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer.

26-12-2019

Breast cancer research : BCR

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes.

07-08-2019

Nature medicine

Publisher Correction: Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

01-07-2019

ESMO open

How I treat MSI cancers with advanced disease.

25-06-2019

Nature medicine

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.

01-06-2019

Insights into imaging

Cryoablation and immunotherapy: an overview of evidence on its synergy.

20-05-2019

Annals of oncology : official journal of the European Society for Medical Oncology

Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors.

01-02-2019

Annals of oncology : official journal of the European Society for Medical Oncology

Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study.

01-01-2019

Oncoimmunology

Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival.

14-12-2018

Seminars in cancer biology

Immuno-oncology-101: overview of major concepts and translational perspectives.

01-10-2018

European journal of cancer (Oxford, England : 1990)

Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).

01-10-2018

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?

01-07-2018

Oncotarget

Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.

26-12-2017

Annals of oncology : official journal of the European Society for Medical Oncology

LAG-3: another brake to release in breast cancer?

01-12-2017

ESMO open

Targeting immune checkpoints in breast cancer: an update of early results.

28-11-2017

JCO precision oncology

Profound Immunotherapy Response in Mismatch Repair-Deficient Breast Cancer.

01-11-2017

Drugs

Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.

01-08-2017

Nederlands tijdschrift voor geneeskunde

[No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer].

22-07-2016

Current opinion in obstetrics & gynecology

Targeting the programmed cell death-1 pathway in breast and ovarian cancer.

01-04-2016

BMC cancer

Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13.

14-08-2015

Molecular oncology

Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.

01-06-2015

Breast (Edinburgh, Scotland)

Additional value of the 70-gene signature and levels of ER and PR for the prediction of outcome in tamoxifen-treated ER-positive breast cancer.

01-12-2012

The EMBO journal

Oestrogen receptor-co-factor-chromatin specificity in the transcriptional regulation of breast cancer.

14-10-2011

Breast cancer research and treatment

PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer.

01-01-2011

Journal of the National Cancer Institute

Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer.

16-12-2009

The Journal of pathology

Mammosphere-derived gene set predicts outcome in patients with ER-positive breast cancer.

01-07-2009

Breast cancer research and treatment

Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.

01-01-2009

Breast cancer research : BCR

A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer.

19-11-2008

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma.

14-05-2003